Table 7 The impact of clinicopathologic parameters on prognosis by univariate analysis
From: Metabolic phenotypes in primary unknown metastatic carcinoma
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
|---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
Age | Â | Â | Â | 0.326 |
 <50 | 20 | 5 | 96 (70–123) |  |
 ≥50 | 39 | 13 | 43 (30–56) |  |
Sex | Â | Â | Â | 0.539 |
 Male | 35 | 10 | 88 (65–110) |  |
 Female | 24 | 8 | 74 (44–103) |  |
Histologic subtype | Â | Â | Â | 0.002 |
 AD | 21 | 11 | 23 (10–36) |  |
 PD | 13 | 1 | 34 (28–40) |  |
 SQ | 17 | 5 | 49 (33–65) |  |
 UD | 8 | 1 | 115 (86–145) |  |
Clinical subtype | Â | Â | Â | <0.001 |
 Nodal type | 25 | 3 | 107 (88–126) |  |
 Single organ type | 10 | 1 | 119 (95–143) |  |
 Intermediate type | 10 | 4 | 21 (9–32) |  |
 Carcinomatosis type | 14 | 10 | 6 (3–10) |  |
Organs involved | Â | Â | Â | 0.701 |
 Lymph node | 38 | 12 | 77 (55–99) |  |
 Bone | 6 | 2 | 40 (18–62) |  |
 Brain | 7 | 1 | 31 (23–39) |  |
 Other | 8 | 3 | 83 (40–126) |  |
Postoperative treatment | Â | Â | Â | 0.638 |
 None | 7 | 1 | 107 (75–139) |  |
 Chemotherapy | 20 | 7 | 77 (45–108) |  |
 Radiation therapy | 15 | 4 | 52 (36–68) |  |
 Chemo-radiation therapy | 17 | 6 | 25 (18–33) |  |